EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Massachusetts General Hospital
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Massachusetts General Hospital (4)
2021
-
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 18, pp. 2005-2015
2019
-
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Oncology, Vol. 20, Núm. 9, pp. 1226-1238
2017
-
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer
Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544
2016
-
A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
Annals of Oncology, Vol. 27, pp. vi98